Kornimate/medical-research-clean huggingface dataset:
l-carnitine in peritoneal dialysis

Conditions: End-Stage Renal Disease

Summary: the development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy. the study hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions containing l-carnitine as an osmotic agent to partially replace glucose.


Eligibility criteria:
inclusion criteria: * age ≥18 years * have a diagnosis of end stage renal disease and have been on continuous ambulatory peritoneal dialysis for at least 3 months * be in a stable clinical condition during the four weeks immediately prior to screening period as demonstrated by medical history, physical examination and laboratory testing * have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with investigators) * have not experienced peritonitis episodes in the last 3 months * be treated with 3 diurnal exchange bag solutions (1.5% or 2.5% glucose) and one nocturnal exchange bag solution (2.5% glucose) * have kt/v urea measurement \> 1.7 per week in a previous test performed within 6 months that should be confirmed at baseline visit * have a minimum weekly creatinine clearance of 45 litres in a previous test performed within 6 months that should be confirmed at baseline visit * have a d/p creatinine ratio at peritoneal equilibration test between 0.50 and 0.81 in a previous test performed within 6 months that should be confirmed at baseline visit * have a d/p glucose ratio at peritoneal equilibration test between 0.26 and 0.49 in a previous test performed within 6 months that should be confirmed at baseline visit * be treated by the participating clinical investigator for a period of at least three months * have understood and signed the informed consent form. exclusion criteria: * have a history of drug or alcohol abuse in the six months prior to entering the protocol * be in treatment with androgens * have diabetes mellitus (as defined by the american diabetes society, objectively documented by a fasting plasma glucose and hba1c determinations) * have clinically significant abnormal liver function test (sgot, sgpt, and gamma-gt \> 2 times the upper normal limit) * have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc) * have a history of congestive heart failure and clinically significant arrhythmia * have an history of epilepsy or any central nervous system disease * have malignancy within the past 5 years, including lymphoproliferative disorders * have any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug, particularly if patient's life expectancy is less than 1 year * have a history of l-carnitine therapy or use in the month prior to entering the protocol * have used any investigational drug in the 3 months prior to entering the protocol * pregnant, lactating, fertility age without protection against pregnancy by adequate contraceptive means

Keywords: peritoneal dialysis l-carnitine
an investigation of rhtpo with different frequencies in the management of itp

Conditions: Immune Thrombocytopenia

Summary: the project was undertaking by qilu hospital of shandong university and other well-known hospitals in china. in order to study the efficacy and safety of different dose and frequency recombinant human thrombopoietin in treating the primary immune thrombocytopenia (itp)

the investigators are undertaking a parallel group, multicentre, randomised controlled trial of 30 primary itp adult patients from 3 medical centers in china. they will be randomly assigned in a 1:1:1 ratio into three groups .the patients in group a (total 10 patients) will receive rhtpo at a dose of 300units/kg ,daily for 14 consecutive days;the patients in group b will receive rhtpo at a dose of 300units/kg ,one times every other day for 7 times.the patients in group c will receive rhtpo at a dose of 300units/kg ,daily for 7 consecutive days .all the patients will follow with a flexible dosage depending on platelet count during the following 12 weeks. platelet counts, bleeding and other symptoms were evaluated before and after treatment, in order to evaluate the efficacy and safety of different dose and frequency recombinant human thrombopoietin in treating the primary immune thrombocytopenia (itp)

Eligibility criteria:
inclusion criteria: 1. subject is ≥18 years old, may be male or female. 2. diagnosed with itp meeting the diagnostic criteria for immune thrombocytopenia. 3. patients who have no response or relapsed after corticosteroid. 4. to show a platelet count \< 30×10\^9/l, and with bleeding manifestations. 5. willing and able to sign written informed consent. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. 2. received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. 3. received high-dose steroids or ivig in the 3 weeks prior to the start of the study. 4. current hiv infection or hepatitis b virus or hepatitis c virus infections. 5. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period. 7. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. 8. patients who are deemed unsuitable for the study by the investigator .

Keywords: recombinant human thrombopoietin dose and frequency immune thrombocytopenia
improving rehabilitation by magnetic brain stimulation

Conditions: Stroke

Summary: we hope to understand the properties of the motor cortex in the brain of people with stroke using non-invasive magnetic stimulation.

this case series assesses the effects of five consecutive days of low-frequency (1 hz) repetitive transcranial magnetic stimulation (rtms) with and without a 6-hz primer. although this paper studies able-bodied individuals, similar rtms protocols are used to facilitate motor recovery in patients with hemiplegia following stroke. however, the cortical mechanisms associated with repeated daily doses of rtms are not completely understood.

Eligibility criteria:
inclusion criteria: * 3-24 months post stroke * upper limb paresis * ces-d below 16, exclusion criteria: * history of seizure * metal in head * score of less than 24 on the folstein mini-mental status exam * clinical judgement of excessive frailty or lack of stamina (e.g. cannot attend to instructions, stay awake, engage in functional activities) * serious uncontrolled medical condition * excessive pain in any joint of the more affected extremity that could limit ability to cooperate with the intervention as judged by the examining clinician

Keywords: cerebrovascular accident rehabilitation
alveoscopy, endoscopic confocal microscopy and lung rejection, parenchymal lung diseases in vivo

Conditions: Lung Transplant

Summary: lung transplantation is indicated when end-stage lung diseases no longer respond to available standard therapy, making life expectancy short and associated with disability. acute and chronic rejection are common complications following transplantation, indicating screening bronchoscopies and transbronchial biopsies at three month intervals the first two years, in addition to clinically indicated procedures when rejection or infection is suspected. transbronchial biopsies carry associated risks (bleeding, pneumothorax). chronic rejection is characterized by progressive obliteration of distal airways (bronchiolitis obliterans-bo-). bo requires open lung biopsy for diagnosis. alternatively, a clinical surrogate (bronchiolitis obliterans syndrome), characterized by decline in forced expired volume in 1 second not explained by acute rejection or infection is used for diagnosis. the new technique of confocal endo-microscopy enables sub-surface visualization of tissue in vivo during bronchoscopic procedures using a probe-based confocal microscope, integrated to a standard endoscope. bronchiolar and alveolar structures can be visualized at a cellular and nuclear level, and these images can be saved and reviewed. this new technology could potentially identify acute and chronic rejection, thus offering and alternative to transbronchial biopsies. we expect to describe a new alternative to diagnose acute and chronic rejection using confocal microscopy images obtained endoscopically, obviating complications of transbronchial biopsies. endoscopic confocal endomicroscopy can detect and classify common bronchiolar and alveolar pathological conditions in real time. specifically, we hypothesize that confocal endomicroscopy images of bronchiolar and alveolar structures during standard bronchoscopy could help to recognize and classify the presence/absence of acute rejection and/or bronchiolitis obliterans syndrome in lung transplant recipients. this technology could also identify the histological characteristics lung diseases such as interstitial, obstructive or vascular end stage lung diseases, and thus lead to more efficient, safer and more accurate diagnosis of these lung conditions during routine bronchoscopies.


Eligibility criteria:
inclusion criteria: 1. age above 18 years 2. any patient undergoing surveillance or clinically indicated bronchoscopies during or after lung transplantation 3. any patient undergoing bronchoscopy prior lung transplant exclusion criteria: 1. unwilling to consent 2. unable to safely tolerate a bronchoscopic procedure

Keywords: lung rejection
personal kinetigraph® clinical validation study

Conditions: Movement Disorders; Parkinson Disease

Summary: the purpose of this study is to clinically validate new measures of the personal kinetigraph® (pkg®).

this is a prospective, observational research study of the personal kinetigraph (pkg) system. the pkg system is intended to quantify kinematics of movement disorder symptoms in conditions such as parkinson's disease, including tremor, bradykinesia and dyskinesia. this study aims to clinically validate new pkg assessments such as walking, device assisted therapy readiness, percent time bradykinesia, percent time dyskinesia, fall prediction, disease progression and non-motor. the clinical validation will require enrollment of both subjects with a diagnosis of movement disorder, such as parkinson's disease, and healthy control subjects who do not a neurological disorder.

Eligibility criteria:
inclusion criteria: * able and willing to sign a written informed consent for study participation * existing diagnosis of a movement disorder or a healthy control subject without diagnosis of a movement disorder exclusion criteria: * bedridden, wheelchair confined, or requires the regular use of an assistive gait device (e.g., walker, cane, etc.) * occupation that involves repetitive movement or complete immobility (e.g., janitor, construction, or sedentary with no/limited arm movements such as a taxi driver) * in the investigator's or sponsor's opinion, subject has any unstable or clinically significant condition that would impair the participant's ability to complete the required pkg watch wear (e.g., subject unable to complete pkg wear instructions per patient instruction manual), complete required assessments or interfere with data collection.
dietary intake of salmon and bone health

Conditions: Osteoporosis

Summary: the aims of this study were to investigate how intake of tailor-made salmon affected bone biomarkers, nutritional status, as well as body composition and bone mineral density. the 122 healthy postmenopausal women included in this 12 weeks intervention study were randomized into four groups: three salmon groups (with three different vitamin d3/vitamin k1 combinations) and one tablet group (vitamin d and calcium).

suboptimal vitamin d status is common among humans, and might have a negative impact on bone health. fatty fish, including atlantic salmon, is an important dietary vitamin d source. however, due to a considerable change in fish feed composition, the contribution of vitamin d from salmon fillet has been reduced. the aims were to investigate how intake of tailor-made salmon affected bone biomarkers, nutritional status (vitamin d, omega-3), as well as body composition and bone mineral density (bmd). the 122 healthy postmenopausal women (median 55 years) included in this 12 weeks intervention study were randomized into four groups: three salmon groups (150 grams/two times/week) and one tablet group (800iu vitamin d and 1000 mg calcium/day). the salmon groups also received calcium supplements (1000 mg/d). the salmon had three different vitamin d3/vitamin k1 combinations: high d3 + high k1, low d3 + high k1, or high d3 + low k1.

Eligibility criteria:
inclusion criteria: * postmenopausal women * caucasian ethnicity * age range 50-65 years * having postmenopausal age of at least one year exclusion criteria: * osteoporotic fractures * medical treatment for osteoporosis * warfarin treatment * creatinine above or below normal range * hypervitaminosis d * malabsorption syndrome * inflammatory bowel disease * inflammatory rheumatic diseases * women who had planned to go away on holiday during the intervention could not participate
us-guided espb versus tpvb on acute and chronic pain after vats

Conditions: Postoperative Pain; Video-Assisted Thoracoscopic Surgery; Thoracic Paravertebral Block; Erector Spinae Plane Block; Acute Pain; Chronic Pain

Summary: postoperative acute and chronic pain is frequently observed in patients undergoing video assisted thoracoscopic surgery (vats). this prolongs the discharge time of patients and increases the frequency of postoperative pulmonary complications. recently, alternative analgesic methods such as thoracic paravertebral block (tpvb) and erector spinae plane block (espb), which are thought to have less side effects than thoracic epidural analgesia, have been used. among these methods, ultrasound (us) guided tpvb is the most preferred method. in addition, espb application is increasing in patients undergoing vats. in the literature, the number of cases performed with espb and randomized controlled prospective studies with espb are increasing. in this study, it is planned to compare the effects of us-guided tpvb and espb on postoperative acute and chronic pain in patients undergoing vats.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * american society of anesthesiologists physical status i-ii-iii * body mass index between 18-30 kg/m2 * patients undergoing elective video assiste thoracoscopic surgery exclusion criteria: * advanced cancer * history of chronic analgesic therapy * history of local anesthetic allergy * infection in the intervention area * patients with bleeding disorders

Keywords: chronic pain erector spinae plane block thoracic paravertebral block acute pain
capacitive diathermy in the lumbopelvic pain

Conditions: Low Back Pain

Summary: objective: to determine the effectiveness of the capacitive diathermy in the mechanosensitivity, morphological, functional and contractility changes in patients with lumbopelvic pain. design: a pilot study, single blind, randomized controlled clinical trial, approved previously by the princess university hospital ethics committee (feb 11, 2016) and the european university clinical intervention review board (cipi/054/15). setting: faculty of health sciences, exercise and sport. european university of madrid. patients and intervention: a sample of 20 patients with bilateral lumbopelvic pain, between 18 and 60 years old, will be recruited and randomized into 2 intervention groups. the instrumental manual therapy with the switched on capacitive diathermy electrode (imt+ t-care®on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (imt+ t-care®off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region. outcome measurements: control variables such as the age, sex, height, weight, body mass index, borg scale physical activity and distress respiratory test will be measured at the beginning of the treatment. dependent variables such as the pain intensity, the pressure pain threshold, the contractility, the stiffness, the adverse effects, the oswestry and schöber test, as well as the ultrasound imaging cross sectional area and thickness of the skin, subcutaneous tissue, connective tissue, l4 multifidus and the abdominal wall (rectus anterior, externus oblique, internal oblique and transversus abdominis) will be assessed before and after each intervention by a blinded examiner. analysis data: the statistical analysis will be performed with a 95% confidence interval and the statistic package social sciences (spss) 22.0.


Eligibility criteria:
inclusion criteria: * bilateral lumbopelvic pain for 6 weeks exclusion criteria: * neuromuscular conditions * negative straight leg raise test * respiratory or congenital conditions * surgeries * neurologic signs * lower extremities conditions * skin alterations * cognitive disorders * body mass index higher than 31 kg/cm2 * skin alterations * pregnancy * intensive physical activity * nijmegen test higher than 24
statin treatment in patients with asthma

Conditions: Asthma

Summary: asthma is a chronic respiratory condition characterized by bronchial hyper-responsiveness secondary to abnormal inflammation of the lung. steroids remain the most effective treatment for this condition. the lipid lowering agents statins have been found to have anti-inflammatory properties. this study is to test the hypothesize that statins will decrease bronchial hyperresponsiveness and inflammation, leading to improved symptoms in patients with asthma.

asthma affects 7 - 12 % of the population in north america and results in substantial morbidity and health care costs. management of asthma is focused towards reducing airway inflammation through a combination of avoidance of inciting and triggering pro-inflammatory agents as well as anti-inflammatory medication. corticosteroids and anti-leukotrienes are efficacious, but are neither universally effective nor free of side effects. statins, which are currently widely prescribed and used safely to improve serum lipids and cholesterol, have anti-inflammatory properties which may be clinically useful in asthma either in addition to or perhaps instead of corticosteroids. the objective of this research proposal is to conduct a randomized placebo controlled trial of 4 weeks statin therapy in patients in moderate to severe but stable asthma. we hypothesize that statins may directly reduce airway inflammation and/or contribute to the anti-inflammatory effects of corticosteroid treatment in these patients. we will measure the effects of statins by measuring airway sensitivity to methacholine, pulmonary function, sputum eosinophils, and quality of life in subjects with asthma after 4 weeks of treatment. statins may become an alternative treatment option or act as steroid sparing agents in patients with asthma.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * moderate to severe asthma based on canadian asthma consensus report * objective evidence of airway hyper-responsiveness (reversible airflow obstruction or positive methacholine challenge in previous two years * on chronic maintenance inhaled corticosteroid therapy. exclusion criteria: * asthma exacerbation within preceding 3 months necessitating any escalation of maintenance medications * chronic oral prednisone use * other respiratory, inflammatory and autoimmune disorder * abnormal baseline creatinine kinase, liver transaminases, or renal disease * history of coronary artery disease, hyperlipidemia, or other condition requiring statin therapy

Keywords: asthma statin
sarcopenia, mobility, physical activity and post-operative risk of bladder carcinoma in the elderly

Conditions: Sarcopenia; Bladder Cancer

Summary: sarcopenia is associated with lower prognosis in solid tumors, but this has not been studied in bladder carcinoma requiring cystectomy. according to ewgsop recommendations, the diagnosis of sarcopenia is based on walking speed, grip strength and muscle mass. these three elements can easily be measured (specially muscle mass measurement by bioimpedencemetry or tomodensitometry). this cohort study will collect clinical complementary elements to better understand the associated factors present with sarcopenia, in order to prepare an interventional preoperative physical reconditioning study. the mobility measurement will be carried out by the qappa questionnaire (validated in french in the elderly) and the quantitative measurement of activity and rest hours during a week by a wrist actimeter. standardized geriatric data will also be collected: adl, iadl for autonomy, mmse for cognitive status, nutritional status (% weight loss, bmi), pain, gds15 for depression screening, updated charlson comorbidity index to identify polypathology and the stopp tool for potentially inappropriate medication. post-operative morbidity mortality at 30 days will be evaluated according to clavien-dindo classification. investigators will also evaluate 6 months geriatric complications : falls, loss of autonomy and decreased mobility and physical activity, cognitive degradation, undernutrition, institutionalization


Eligibility criteria:
inclusion criteria: * confirmed urothelial bladder carcinoma ( rtuv) * indication of radical cystectomy * able, informed and with informed consent for the study * affiliated to the social security system * talking french exclusion criteria: * life expectancy \<6 months * other active malignant tumors or other severe concomitant chronic pathologies affecting the general condition of the patient and / or likely to limit compliance with the requirements of the study. * treatments incompatible with the study: previous corticosteroid treatment prolonged for more than one month (induces iatrogenic sarcopenia).

Keywords: physical activity elderly